Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial
Kanwal Raghav, Salvatore Siena, Atsuo Takashima, et al.
The Lancet Oncology (2024) Vol. 25, Iss. 9, pp. 1147-1162
Closed Access | Times Cited: 15

Showing 15 citing articles:

Accelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical Trials
Jia Liu, M. Farrow, Lesley Seymour, et al.
Journal of Clinical Oncology (2025)
Closed Access | Times Cited: 1
EGFR-directed antibodies promote HER2 ADC internalization and efficacy
Avantika Gupta, Flavia Michelini, Hong Shao, et al.
Cell Reports Medicine (2024) Vol. 5, Iss. 11, pp. 101792-101792
Open Access | Times Cited: 5
Trastuzumab Deruxtecan wirkt auch bei RAS-mutierten kolorektalen Karzinomen

Zeitschrift für Gastroenterologie (2025) Vol. 63, Iss. 02, pp. 122-123
Closed Access
Six events that shaped antibody approvals in oncology
Suman Paul, Shibin Zhou
Frontiers in Immunology (2025) Vol. 16
Open Access
What Is Next for Refractory Colorectal Cancer CRC? Looking Beyond SUNLIGHT, FRESCO2, RECURSE and CORRECT
Sara Cherri, Michela Libertini, Silvia Noventa, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 6, pp. 2522-2522
Open Access
Expanding the potential of antibody–drug conjugates in gastrointestinal malignancies: beyond HER2 targets
Panagiotis Ntellas, Avani Athauda, Kemmyo Sugiyama, et al.
ESMO Gastrointestinal Oncology (2025) Vol. 8, pp. 100154-100154
Closed Access
Antibody–drug conjugates in rare genitourinary tumors: review and perspectives
Andre Rashad Kydd, Md Shahid Sarwar, Saad Omar Atiq, et al.
Current Opinion in Oncology (2025)
Closed Access
Emerging Paradigms in Genitourinary Cancers: Integrating Molecular Imaging, Hypoxia-Inducible Factor–Targeted Therapies, and Antibody-Drug Conjugates in Renal Cell and Urothelial Carcinomas
Rana R. McKay, Renu Eapen, Elizabeth Wulff‐Burchfield, et al.
American Society of Clinical Oncology Educational Book (2025) Vol. 45, Iss. 3
Closed Access
HER2 testing: evolution and update for a companion diagnostic assay
Charles T. Robbins, Katherine M. Bates, David L. Rimm
Nature Reviews Clinical Oncology (2025)
Closed Access
Patterns of HER2 expression and genomic correlates in lung cancer, with a focus on preanalytical variables impacting immunohistochemical staining results
Cristiana M. Pineda, Lauren O’Loughlin, Benjamin Heyman, et al.
Journal of Clinical Pathology (2025), pp. jcp-210095
Closed Access
Late-line options for patients with metastatic colorectal cancer: a review and evidence-based algorithm
Paolo Ciracì, Vittorio Studiale, Ada Taravella, et al.
Nature Reviews Clinical Oncology (2024)
Closed Access | Times Cited: 2
Trastuzumab deruxtecan in HER2-positive metastatic colorectal cancer: less is more?
Jeanine Roodhart, Miriam Koopman
The Lancet Oncology (2024) Vol. 25, Iss. 9, pp. 1104-1105
Closed Access | Times Cited: 1
When destiny doesn’t pan out: Implications for the treatment of sarcomas after the agnostic approval of trastuzumab deruxtecan
Brian Schulte, Caleb Hwang, Andrew E. Horvai, et al.
Cancer (2024) Vol. 130, Iss. 23, pp. 4020-4024
Closed Access | Times Cited: 1
Molecular mechanisms of HER2-targeted therapy and strategies to overcome the drug resistance in colorectal cancer
Rui Zhang, Chang Su, Yong-liang Jia, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 179, pp. 117363-117363
Open Access | Times Cited: 1
The emerging HER2 landscape in colorectal cancer: the key to unveil the future treatment algorithm?
Jacopo Venturini, Giulia Massaro, Daniele Lavacchi, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 204, pp. 104515-104515
Open Access | Times Cited: 1
Precision Medicine for Metastatic Colorectal Cancer: Where Do We Stand?
Patrick W. Underwood, Timothy M. Pawlik
Cancers (2024) Vol. 16, Iss. 22, pp. 3870-3870
Open Access | Times Cited: 1
Metastatic colon cancer: clinical practice guideline update in 2024
М. Yu. Fedyanin, O. A. Gladkov, S. S. Gordeyev, et al.
Surgery and Oncology (2024) Vol. 14, Iss. 4, pp. 31-42
Closed Access
Page 1

Scroll to top